AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35902229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured aneurysm coiling
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: Ruptured aneurysm clipping
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: aSAH in-hospital mortality
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: aSAH admissions
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: Mild aSAH presentations
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: Moderate aSAH presentations
Number of subjects: 16247
Study 35902229 — intervention group
Group type: COMPARATOR
Intervention: Higher severity aSAH presentations
Number of subjects: 16247
Study 35902389 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger infants (<3 months)
Number of subjects: 325
Study 35902389 — intervention group
Group type: EXPERIMENTAL
Intervention: Older infants (≥6 months)
Number of subjects: 325
Study 35902389 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-A and RSV-B
Number of subjects: 325
Study 35902389 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with severe RSV infection (higher ReSViNET score, fever, hospitalization, intensive care)
Number of subjects: 325
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 ESC classification
Number of subjects: 15773
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: 2021 ESC classification
Number of subjects: 15773
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD + TOD
Number of subjects: 15773
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCVD only
Number of subjects: 15773
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 3 additional ASCVD risk factors
Number of subjects: 15773
Study 35902419 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TOD
Number of subjects: 15773
Study 35902798 — intervention group
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (radiotherapy: 45 Gy/25 f and concurrent chemotherapy: S-1: 40-60 mg twice a day, followed by six cycles of consolidated chemotherapy (SOX: S-1 and oxaliplatin) and surgery
Number of subjects: 0
Study 35902809 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight management program (MOVE UP), 13-month duration
Number of subjects: 29
Study 35902867 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7 (TXA-127)
Number of subjects: 0
Study 35902867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35903159 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment Story Completion Task scales
Number of subjects: 0
Study 35903159 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal attachment and mental health
Number of subjects: 0
Study 35903445 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum serine levels (Q2, Q3, Q4)
Number of subjects: 20702
Study 35903445 — intervention group
Group type: COMPARATOR
Intervention: Control group (Q1)
Number of subjects: 20702
Study 35903448 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (2.4 g/day) plus venlafaxine
Number of subjects: 72
Study 35903448 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus venlafaxine
Number of subjects: 72
Study 35903458 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe underweight (weight-for-age z-scores [WAZ] < -3)
Number of subjects: 0
Study 35903458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression for anthropometric indicators
Number of subjects: 0
Study 35903636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive re-nutrition
Number of subjects: 36
Study 35903678 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat shock protein peptide complex 96 (HSPPC-96) vaccination
Number of subjects: 0
Study 35904231 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative selective HSCT
Number of subjects: 226
Study 35904231 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative selective HSCT
Number of subjects: 226
Study 35904231 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative non-selective HSCT
Number of subjects: 226
Study 35904231 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 226
Study 35904632 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 56
Study 35904632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 35904671 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes, and biosampling.
Number of subjects: 5298
Study 35904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) before vitrectomy
Number of subjects: 52
Study 35904708 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) at the end of vitrectomy
Number of subjects: 52
Study 35904722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag at 3 mg for up to 7 days
Number of subjects: 35
Study 35904853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution features derived from wearable data
Number of subjects: 692
Study 35904853 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate dynamics in sedentary states
Number of subjects: 692
Study 35904853 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate dynamics in active states
Number of subjects: 692
Study 35904853 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resolution patterns in wearable heart rate recordings
Number of subjects: 692
Study 35904867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabkompassen (intervention group)
Number of subjects: 28
Study 35904867 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient visits (control group)
Number of subjects: 28
Study 35904867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabkompassen at 12-month follow-up
Number of subjects: 28
Study 35904867 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (primary outcome)
Number of subjects: 28
Study 35904867 — intervention group
Group type: EXPERIMENTAL
Intervention: Various stroke impacts (secondary outcomes)
Number of subjects: 28
Study 35904878 — intervention group
Group type: EXPERIMENTAL
Intervention: You Cope, We Support (YCWS) - self-management relaxation exercises
Number of subjects: 170
Study 35904878 — intervention group
Group type: COMPARATOR
Intervention: Control group - self-monitoring of outcomes and alerts or reminders
Number of subjects: 170
Study 35904987 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine containing 120 μg of RSVPreF3
Number of subjects: 1053
Study 35904987 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted vaccine
Number of subjects: 1053
Study 35904987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: ARISCAT risk index
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA III
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: High ARISCAT grades
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin < 35g/L
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, male gender, duration of surgery, duration of OLV
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative albumin levels
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative average visual analogue scale (VAS) score for pain at the 24th-hour
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay in the postoperative intensive care unit
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal time
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge time
Number of subjects: 120
Study 35905198 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity and mortality on the 90th-day
Number of subjects: 120
Study 35905224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with remifentanil followed by propofol administration
Number of subjects: 50
Study 35905229 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor Fecal Microbiota Transplantation (FMT)
Number of subjects: 34
Study 35905294 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 134
Study 35905428 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU diary
Number of subjects: 854
Study 35905860 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 41
Study 35905860 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial signature at T1
Number of subjects: 41
Study 35905860 — intervention group
Group type: EXPERIMENTAL
Intervention: PD index at T1
Number of subjects: 41
Study 35905860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorea sp. abundance at T1
Number of subjects: 41
Study 35905860 — intervention group
Group type: EXPERIMENTAL
Intervention: KEGG pathways at T1
Number of subjects: 41
Study 35906349 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian 60 mg single oral dose
Number of subjects: 8
Study 35906574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced adherence counseling (EAC)
Number of subjects: 136
Study 35906574 — intervention group
Group type: COMPARATOR
Intervention: Facility-based, individual EAC counseling
Number of subjects: 136
Study 35906574 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-suggested improvements to EAC
Number of subjects: 136
Study 35906589 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT intervention (modified for Quality)
Number of subjects: 0
Study 35906602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple data collection methods (interviews, observations, facilitator sessions)
Number of subjects: 0
Study 35906602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple data collection methods
Number of subjects: 0
Study 35906602 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic methods (co-occurrence table, k-means clustering, taxonomic analysis)
Number of subjects: 0
Study 35906602 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation types
Number of subjects: 0
Study 35906608 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history of Type 1 SMA (no specific intervention mentioned)
Number of subjects: 60
Study 35906656 — intervention group
Group type: EXPERIMENTAL
Intervention: In-situ simulation training
Number of subjects: 71
Study 35906676 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 35906676 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 35906676 — intervention group
Group type: EXPERIMENTAL
Intervention: TMI model
Number of subjects: 0
Study 35906676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohorts from POPLAR and OAK trials
Number of subjects: 0
Study 35906699 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week complementary and alternative medicine (CAM) program delivered by a therapist at a clinic; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Number of subjects: 837
Study 35906699 — intervention group
Group type: COMPARATOR
Intervention: 12-week complementary and alternative medicine (CAM) program initiated by the participant at home using a tablet and pre-recorded videos; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Number of subjects: 837
Study 35906831 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (empiric therapy)
Number of subjects: 549
Study 35906831 — intervention group
Group type: COMPARATOR
Intervention: Preemptive antifungal strategy (arm B)
Number of subjects: 549
Study 35906881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-spike neutralizing monoclonal antibodies (nMoAbs)
Number of subjects: 91
Study 35907107 — intervention group
Group type: EXPERIMENTAL
Intervention: LBBAP
Number of subjects: 20
Study 35907107 — intervention group
Group type: EXPERIMENTAL
Intervention: LOT-CRT
Number of subjects: 20
Study 35907135 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day; 0.75 mg/day for moderate renal impairment)
Number of subjects: 19
Study 35907408 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical bone marrow transplantation
Number of subjects: 32
Study 35907430 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG low dose (5×10^10 viral particles), n=3
Number of subjects: 12
Study 35907430 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG middle dose (5×10^10 viral particles), n=3
Number of subjects: 12
Study 35907430 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx2 RabG high dose (5×10^10 viral particles), n=6
Number of subjects: 12
Study 35907430 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year for middle-dose or high-dose recipients
Number of subjects: 12
Study 35907430 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of a licensed rabies vaccine after ChAdOx2 RabG
Number of subjects: 12
Study 35907438 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT duration <6 months (n=273)
Number of subjects: 1827
Study 35907438 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT duration 6 to 12 months (n=477)
Number of subjects: 1827
Study 35907438 — intervention group
Group type: COMPARATOR
Intervention: DAPT duration 12 to 24 months (n=637)
Number of subjects: 1827
Study 35907438 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT duration ≥ 24 months (n=440)
Number of subjects: 1827
Study 35907755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low temperature cryoablation (ULTC)
Number of subjects: 78
Study 35907978 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics therapy (Etanercept, Abatacept, Tocilizumab)
Number of subjects: 480
Study 35907978 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (concomitant treatment)
Number of subjects: 480
Study 35908067 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) for 6 weeks
Number of subjects: 23
Study 35908067 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day bladder diary
Number of subjects: 23
Study 35908067 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIUS
Number of subjects: 23
Study 35908067 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIQ-OAB
Number of subjects: 23
Study 35908067 — intervention group
Group type: EXPERIMENTAL
Intervention: KHQ
Number of subjects: 23
Study 35908120 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient guide 'Are Mammograms Still Right for Me?'
Number of subjects: 45
Study 35908242 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (inotersen-inotersen)
Number of subjects: 109
Study 35908242 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Inotersen (placebo-inotersen)
Number of subjects: 109
Study 35908658 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel press-fit Percutaneous Osseointegrated Prosthesis (POP)
Number of subjects: 10
Study 35908658 — intervention group
Group type: COMPARATOR
Intervention: Socket suspension system
Number of subjects: 10
Study 35908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily for 10 days
Number of subjects: 8156
Study 35908569 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 8156
Study 35908569 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK inhibitors (including baricitinib) in meta-analysis
Number of subjects: 8156
Study 35908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib or another JAK inhibitor in updated meta-analysis
Number of subjects: 8156
Study 35909174 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PEEP by 50% above baseline
Number of subjects: 27
Study 35909174 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PEEP
Number of subjects: 27
Study 35909174 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnodynamic monitoring
Number of subjects: 27
Study 35909213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 264
Study 35909213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 35909213 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (post hoc analysis)
Number of subjects: 264
Study 35909254 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines during the first trimester
Number of subjects: 1053
Study 35909254 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric medications other than benzodiazepines
Number of subjects: 1053
Study 35909297 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for gestational diabetes based on maternal demographics and clinical parameters.
Number of subjects: 3263
Study 35909569 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 392
Study 35909569 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib
Number of subjects: 392
Study 35910354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine, dosage and duration not available
Number of subjects: 0
Study 35910354 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific intervention details not available
Number of subjects: 0
Study 35910889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal metabolic indicators (insulin, glucose, insulin growth factor 1, hemoglobin A1c) at early pregnancy (<15 and 26-28 weeks of gestation)
Number of subjects: 1954
Study 35910889 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary intake and mental health problems derived from the COVID-19 pandemic
Number of subjects: 1954
Study 35911528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-managed warfarin therapy (PMWT)
Number of subjects: 59
Study 35911528 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 59
Study 35911547 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach combining clinical, imaging, biological and electrocardiographic markers
Number of subjects: 240
Study 35911547 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach
Number of subjects: 240
Study 35911547 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 ≧ 9 ng/ml
Number of subjects: 240
Study 35911663 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherectomy and DCB (Drug-Coated Balloon)
Number of subjects: 2895
Study 35911663 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 2895
Study 35911702 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction immunochemotherapy (iIC) with PD-1 inhibitor plus chemotherapy every 3 weeks for at least two cycles
Number of subjects: 155
Study 35911702 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (iC)
Number of subjects: 155
Study 35911702 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion surgery following immunochemotherapy
Number of subjects: 155
Study 35911702 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAE)
Number of subjects: 155
Study 35911824 — intervention group
Group type: EXPERIMENTAL
Intervention: Stoss therapy
Number of subjects: 41
Study 35911824 — intervention group
Group type: COMPARATOR
Intervention: Standard of care vitamin D supplementation
Number of subjects: 41
Study 35911899 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolong Life with Nine Turn method (PLWNT) Qigong
Number of subjects: 34
Study 35911899 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 34
Study 35912221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosecond pulsed electric field (nsPEF)
Number of subjects: 192
Study 35912650 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET)
Number of subjects: 363
Study 35912650 — intervention group
Group type: COMPARATOR
Intervention: Control (older patients, matched cohort)
Number of subjects: 363
Study 35912709 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine use
Number of subjects: 66299
Study 35912709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 66299
Study 35912709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 66299
Study 35912709 — intervention group
Group type: COMPARATOR
Intervention: Alcohol abuse
Number of subjects: 66299
Study 35912709 — intervention group
Group type: COMPARATOR
Intervention: Cocaine use
Number of subjects: 66299
Study 35913400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab
Number of subjects: 0
Study 35913436 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high coffee and/or tea consumption (≥4 cups/day)
Number of subjects: 3788
Study 35913436 — intervention group
Group type: EXPERIMENTAL
Intervention: High coffee and/or tea consumption (3 cups/day)
Number of subjects: 3788
Study 35913436 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate coffee and/or tea consumption (2 cups/day)
Number of subjects: 3788
Study 35913436 — intervention group
Group type: COMPARATOR
Intervention: Low coffee and/or tea consumption (<1 cup/day)
Number of subjects: 3788
Study 35913563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 18
Study 35913656 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Suspend (PLGS) duration > 157.5 min/day
Number of subjects: 110
Study 35913656 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGS duration ≤ 174.4 min/day
Number of subjects: 110
Study 35913656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily PLGS duration between 157.5 and 174.4 min/day
Number of subjects: 110
Study 35913656 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin percentage < 52.0%
Number of subjects: 110
Study 35913656 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Daily Dose (TDD) adaptation
Number of subjects: 110